Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 298Carcinoma, Non-Small-Cell Lung 226Neoplasms 155Prostatic Neoplasms 154Multiple Myeloma 116Neoplasm Metastasis 83Colorectal Neoplasms 80Leukemia, Myeloid, Acute 74Lung Neoplasms 71Parkinson Disease 4, Autosomal Dominant Lewy Body 68Melanoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Follicular 62Lymphoma, Non-Hodgkin 61Papillomavirus Infections 59Leukemia 59Pain 52Lymphoma 52Uterine Cervical Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Ovarian Neoplasms 47Carcinoma, Hepatocellular 46Keratosis, Actinic 44Carcinoma, Renal Cell 44Recurrence 43Head and Neck Neoplasms 43Stomach Neoplasms 38Lymphoma, Large B-Cell, Diffuse 34Urinary Bladder Neoplasms 33Squamous Cell Carcinoma of Head and Neck 32

Interventions

Amifampridine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Has results × Lambert-Eaton Myasthenic Syndrome × Clear all
NCT02970162 2018-12-24

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals, Inc.

Phase 3 Completed
26 enrolled 10 charts

Lambert-Eaton Myasthenic Syndrome

NCT01377922 2018-01-04

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals, Inc.

Phase 3 Completed
38 enrolled 12 charts

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡